Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Stopped Terminated: Amgen decision following Primary Analysis. Not due to safety reason

Conditions

• Breast Cancer

Interventions

• DRUG: Placebo
• DRUG: Denosumab

Sponsor

Amgen

Collaborators

• [object Object]